About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker BIIB · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
May 22, 2026TOFIDENCE
TOCILIZUMAB-BAVI
BIIB
Biogen Ma
Biologic (BLA), supplement
BIOSIMILAR
BLA761354 ↗
Apr 20, 2026ZURZUVAE
ZURANOLONE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA217369 ↗
Apr 7, 2026SKYCLARYS
OMAVELOXOLONE
BIIB
Biogen US
New drug (NDA), supplement
Labeling
NDA216718 ↗
Mar 27, 2026SPINRAZA
NUSINERSEN SODIUM
BIIB
Biogen
New drug (NDA), supplement
Efficacy
NDA209531 ↗
Mar 18, 2025TYSABRI
NATALIZUMAB
BIIB
Biogen Idec
Biologic (BLA), supplement
Labeling
BLA125104 ↗
Mar 6, 2025TOFIDENCE
TOCILIZUMAB-BAVI
BIIB
Biogen Ma
Biologic (BLA), supplement
Labeling
BLA761354 ↗
Dec 20, 2024SKYCLARYS
OMAVELOXOLONE
BIIB
Biogen US
New drug (NDA), supplement
Labeling
NDA216718 ↗
Dec 20, 2024SKYCLARYS
OMAVELOXOLONE
BIIB
Biogen US
New drug (NDA), supplement
Efficacy
NDA216718 ↗
Dec 3, 2024TOFIDENCE
TOCILIZUMAB-BAVI
BIIB
Biogen Ma
Biologic (BLA), supplement
Labeling
BLA761354 ↗
Sep 11, 2024VUMERITY
DIROXIMEL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Manufacturing (CMC)
NDA211855 ↗
Jul 31, 2024ZURZUVAE
ZURANOLONE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA217369 ↗
Jul 22, 2024TOFIDENCE
TOCILIZUMAB-BAVI
BIIB
Biogen Ma
Biologic (BLA), supplement
BIOSIMILAR
BLA761354 ↗
Apr 10, 2024SPINRAZA
NUSINERSEN SODIUM
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA209531 ↗
Letter or label ↗
Apr 10, 2024SPINRAZA
NUSINERSEN SODIUM
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA209531 ↗
Letter or label ↗
Mar 22, 2024VUMERITY
DIROXIMEL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA211855 ↗
Mar 15, 2024ADUHELM
ADUCANUMAB-AVWA
BIIB
Biogen Inc
Biologic (BLA), supplement
Manufacturing (CMC)
BLA761178 ↗
Mar 12, 2024TECFIDERA
DIMETHYL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA204063 ↗
Jan 25, 2024SKYCLARYS
OMAVELOXOLONE
BIIB
Biogen US
New drug (NDA), supplement
Labeling
NDA216718 ↗
Dec 13, 2023VUMERITY
DIROXIMEL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA211855 ↗
Dec 13, 2023TECFIDERA
DIMETHYL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA204063 ↗
Oct 30, 2023TYSABRI
NATALIZUMAB
BIIB
Biogen Idec
Biologic (BLA), supplement
Labeling
BLA125104 ↗
Oct 25, 2023TYSABRI
NATALIZUMAB
BIIB
Biogen Idec
Biologic (BLA), supplement
Labeling
BLA125104 ↗
Sep 29, 2023TOFIDENCE
TOCILIZUMAB-BAVI
BIIB
Biogen Ma
Biologic (BLA)
UNKNOWN
BLA761354 ↗
Aug 30, 2023ADUHELM
ADUCANUMAB-AVWA
BIIB
Biogen Inc
Biologic (BLA), supplement
Labeling
BLA761178 ↗
Aug 24, 2023TYSABRI
NATALIZUMAB
BIIB
Biogen Idec
Biologic (BLA), supplement
REMS
BLA125104 ↗
Aug 4, 2023ZURZUVAE
ZURANOLONE
BIIB
Biogen
New drug (NDA)
Type 1 - New Molecular Entity
NDA217369 ↗
Jul 28, 2023PLEGRIDY
PEGINTERFERON BETA-1A
BIIB
Biogen Idec Inc
Biologic (BLA), supplement
Labeling
BLA125499 ↗
Jul 28, 2023AVONEX, AVONEX PEN
INTERFERON BETA-1A
BIIB
Biogen
Biologic (BLA), supplement
Labeling
BLA103628 ↗
Apr 25, 2023QALSODY
TOFERSEN
BIIB
Biogen Ma
New drug (NDA)
Type 1 - New Molecular Entity
NDA215887 ↗
Apr 11, 2023TYSABRI
NATALIZUMAB
BIIB
Biogen Idec
Biologic (BLA), supplement
Labeling
BLA125104 ↗
Apr 11, 2023TYSABRI
NATALIZUMAB
BIIB
Biogen Idec
Biologic (BLA), supplement
REMS
BLA125104 ↗
Feb 28, 2023SKYCLARYS
OMAVELOXOLONE
BIIB
Biogen US
New drug (NDA)
Type 1 - New Molecular Entity
NDA216718 ↗
Feb 17, 2023SPINRAZA
NUSINERSEN SODIUM
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA209531 ↗
Feb 10, 2023VUMERITY
DIROXIMEL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Efficacy
NDA211855 ↗
Feb 10, 2023TECFIDERA
DIMETHYL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Efficacy
NDA204063 ↗
Feb 8, 2023ADUHELM
ADUCANUMAB-AVWA
BIIB
Biogen Inc
Biologic (BLA), supplement
Efficacy
BLA761178 ↗
Nov 16, 2022VUMERITY
DIROXIMEL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Manufacturing (CMC)
NDA211855 ↗
Sep 29, 2022VUMERITY
DIROXIMEL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA211855 ↗
Sep 29, 2022TECFIDERA
DIMETHYL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA204063 ↗
Letter or label ↗
Sep 29, 2022TECFIDERA
DIMETHYL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA204063 ↗
Letter or label ↗
Apr 29, 2022ADUHELM
ADUCANUMAB-AVWA
BIIB
Biogen Inc
Biologic (BLA), supplement
Labeling
BLA761178 ↗
Mar 29, 2022PLEGRIDY
PEGINTERFERON BETA-1A
BIIB
Biogen Idec Inc
Biologic (BLA), supplement
Labeling
BLA125499 ↗
Feb 10, 2022VUMERITY
DIROXIMEL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA211855 ↗
Feb 10, 2022TECFIDERA
DIMETHYL FUMARATE
BIIB
Biogen
New drug (NDA), supplement
Labeling
NDA204063 ↗
Letter or label ↗
Dec 10, 2021TYSABRI
NATALIZUMAB
BIIB
Biogen Idec
Biologic (BLA), supplement
Labeling
BLA125104 ↗
Letter or label ↗
Dec 10, 2021TYSABRI
NATALIZUMAB
BIIB
Biogen Idec
Biologic (BLA), supplement
Labeling
BLA125104 ↗
Letter or label ↗
Nov 3, 2021PLEGRIDY
PEGINTERFERON BETA-1A
BIIB
Biogen Idec Inc
Biologic (BLA), supplement
Labeling
BLA125499 ↗
Nov 3, 2021AVONEX, AVONEX PEN
INTERFERON BETA-1A
BIIB
Biogen
Biologic (BLA), supplement
Labeling
BLA103628 ↗
Jul 7, 2021ADUHELM
ADUCANUMAB-AVWA
BIIB
Biogen Inc
Biologic (BLA), supplement
Labeling
BLA761178 ↗
Letter or label ↗
Jun 7, 2021ADUHELM
ADUCANUMAB-AVWA
BIIB
Biogen Inc
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761178 ↗
Letter or label ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:27 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates